Vascular therapy for XXXX .

@entity32 @entity18518 @entity82 @entity12186 @entity519 @entity35 @entity6667 @entity2335 @entity2880
PURPOSE: The underlying pathology of @entity2335 is cellular and vascular damage followed by increased @entity82 and @entity32 . This study was to determine if neovascular-promoting therapy could reduce the pathological changes in the bladder wall associated with pelvic irradiation. METHODS: Adult female Lewis inbred @entity35 were irradiated with a single dose of 20 Gy directed at their bladder. Four weeks later, 30 @entity35 were divided equally into one of three treatment groups for bladder wall injection of: (1) PBS (Control); (2) PBS containing 50 ng vascular endothelial growth factor ( @entity6667 (165)); or (3) PBS containing 1   10(6) @entity35 endothelial cells (EC). Age-matched non-irradiated @entity35 (n = 10) served as untreated controls. At either 1.5 or 3 months following radiation, bladders were analyzed for collagen deposition using Masson's Trichrome staining of collagen and muscle and vascularization using @entity2880 factor staining of ECs. Quantitative-PCR was used to examine markers of angiogenesis, @entity519 , and @entity82 . RESULTS: The collagen/muscle ratio was doubled in the control group 3 months post-irradiation (P < 0.05 vs. non-irradiated bladders). Both ECs and @entity6667 inhibited increases in collagen content (P < 0.05 vs. control). Similarly, irradiation reduced bladder wall vessel counts compared to non-irradiated controls (P < 0.05) and both ECs and @entity6667 maintained vessel counts similar to that of non-irradiated controls (P < 0.05). PCR analysis showed a higher expression of neovascular markers ( @entity18518 , @entity12186 ) in the EC and @entity6667 groups compared to non-irradiated controls (P < 0.05). CONCLUSIONS: Angiogenesis therapy may be useful in the prevention and/or treatment of the underlying pathology of @entity2335 .
